Obinutuzumab is a glycoengineered type II anti-CD20 monoclonal antibody (mAb), recognizing a unique CD20 extracellular membrane epitope with enhanced antibody dependent cellular cytotoxicity (ADCC) vs rituximab. We hypothesize that obinutuzumab vs rituximab will significantly enhance in-vitro and in-vivo cytotoxicity against PMBL.
Obinutuzumab vs. rituximab in follicular lymphoma explained in Quick Take video:
Rituximab, the first anti-CD20 monoclonal antibody, has dramatically improved outcomes for patients with B-cell lymphoproliferative disorders. Obinutuzumab was developed to potentiate activity and overcome resistance to rituximab. Clinical data suggest that obinutuzumab is superior to rituximab in f
To compare the safety of obinutuzumab by: 5. Comparing how well obinutuzumab versus rituximab in treating the disease. 6. Comparing the
The GALLIUM study showed a progression-free survival advantage of 7% in favor of obinutuzumab vs. rituximab-based immunochemotherapies as first-line therapy in follicular lymphoma (FL) patients. Yet, the toxicity appears to be increased with obinutuzumab-based therapy. This is a multicenter retrospective-cohort study including adult FL patients comparing the toxicity of first-line rituximab vs
targeted drugs, such as ibrutinib antibody therapies, such as rituximab or obinutuzumab. When rituximab is given with chemotherapy, the regimen
This may explain why obinutuzumab improve PFS of CD20 NHL patients compared with rituximab. Although obinutuzumab-based therapy significantly prolonged PFS compared with rituximab-based therapy
In vitro, the obinutuzumab-induced antibody-dependent cell-mediated cytotoxicity is times higher than rituximab, and obinutuzumab induces
by Y Chu Cited by 7vs rituximab. We hypothesize that obinutuzumab vs rituximab will significantly enhance in-vitro and in-vivo cytotoxicity against PMBL. PMBL
then vs than
accept vs expect
alright vs all right
its vs it's
there vs their
waist vs waste
your vs you're, you are